A pooled analysis based on the REACH and REACH-2 trials also confirmed these results for advanced HCC patients with AFP ≥ 400 ng/mL, showing a higher benefit in the OS group vs. the placebo (OS 8.1 vs. 5.0 months; HR = 0.69; p = 0.0002) [124]. The gene discussed is AFP; the disease is hepatocellular carcinoma.